Formoterol counteracts the inhibitory effect of cigarette smoke on glucocorticoid-induced leucine zipper (GILZ) transactivation in human bronchial smooth muscle cells.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 May 2019
Historique:
received: 15 06 2018
revised: 06 02 2019
accepted: 08 02 2019
pubmed: 13 2 2019
medline: 7 8 2019
entrez: 13 2 2019
Statut: ppublish

Résumé

Cigarette smokers with asthma and chronic obstructive pulmonary disease (COPD) are less responsive to glucocorticoids (GCs). The anti-inflammatory action of GCs depends also on their ability to transactivate genes such as GC-induced leucine zipper (GILZ). We investigated the effects of aqueous cigarette smoke extract (CSE) on GILZ transactivation evoked by 17-beclomethasone monopropionate (BMP) or fluticasone propionate (FP) in the presence or absence of the long acting β2-adrenoceptor agonist (LABA) bronchodilator formoterol or salmeterol in human primary cultures of human bronchial smooth muscle cells (HBSMC). We monitored GC receptor Ser211 phosphorylation by western blot analysis and GC receptor nuclear translocation by immunostaining followed high-content imaging analysis. BMP, as well as FP, induced GILZ expression in a concentration-dependent manner (EC

Identifiants

pubmed: 30753866
pii: S0014-2999(19)30101-3
doi: 10.1016/j.ejphar.2019.02.010
pii:
doi:

Substances chimiques

Receptors, Glucocorticoid 0
TSC22D3 protein, human 0
Transcription Factors 0
beclomethasone 17-monopropionate 5BGA9FD55H
Beclomethasone KGZ1SLC28Z
Formoterol Fumarate W34SHF8J2K

Types de publication

Journal Article

Langues

eng

Pagination

8-14

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Gessica Marchini (G)

Department of Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy.

Silvia Carnevali (S)

Department of Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy.

Fabrizio Facchinetti (F)

Department of Pharmacology and Toxicology, Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy. Electronic address: f.facchinetti@chiesi.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH